secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001641172-25-022974
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IMDX Q2 rev $518K, net loss $9.7M; FDA on track for GraftAssureDx submission by year-end
--------------------------------------------------------------------------------

- Revenue $518K vs $104K YoY; gross margin 67.6%, up from 62% in Q1.
- Net loss $9.7M ($0.30/sh); non-GAAP operating loss $5.98M.
- Cash $26.0M; quarterly cash spend ~$6M, in line with target.
- FDA submission for GraftAssureDx on track for end-2025; marketing authorization expected mid-2026.
- First RUO kit sale to Swiss hospital; Medicare boost to $2,753/test.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000164117225022974/0001641172-25-022974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000164117225022974/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-022974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer